JP2017501728A5 - - Google Patents

Download PDF

Info

Publication number
JP2017501728A5
JP2017501728A5 JP2016543004A JP2016543004A JP2017501728A5 JP 2017501728 A5 JP2017501728 A5 JP 2017501728A5 JP 2016543004 A JP2016543004 A JP 2016543004A JP 2016543004 A JP2016543004 A JP 2016543004A JP 2017501728 A5 JP2017501728 A5 JP 2017501728A5
Authority
JP
Japan
Prior art keywords
antibody
antigen
amino acid
binding fragment
terminal amino
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2016543004A
Other languages
English (en)
Japanese (ja)
Other versions
JP2017501728A (ja
JP6585600B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/CA2014/051263 external-priority patent/WO2015095972A1/en
Publication of JP2017501728A publication Critical patent/JP2017501728A/ja
Publication of JP2017501728A5 publication Critical patent/JP2017501728A5/ja
Application granted granted Critical
Publication of JP6585600B2 publication Critical patent/JP6585600B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2016543004A 2013-12-23 2014-12-23 C末端軽鎖ポリペプチド伸長を含有する抗体、ならびにその複合体及びその使用方法 Active JP6585600B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201361920425P 2013-12-23 2013-12-23
US61/920,425 2013-12-23
PCT/CA2014/051263 WO2015095972A1 (en) 2013-12-23 2014-12-23 Antibodies comprising c-terminal light chain polypeptide extensions and conjugates and methods of use thereof

Publications (3)

Publication Number Publication Date
JP2017501728A JP2017501728A (ja) 2017-01-19
JP2017501728A5 true JP2017501728A5 (enExample) 2018-02-01
JP6585600B2 JP6585600B2 (ja) 2019-10-02

Family

ID=53477259

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2016543004A Active JP6585600B2 (ja) 2013-12-23 2014-12-23 C末端軽鎖ポリペプチド伸長を含有する抗体、ならびにその複合体及びその使用方法

Country Status (13)

Country Link
US (1) US11208497B2 (enExample)
EP (1) EP3087185A4 (enExample)
JP (1) JP6585600B2 (enExample)
KR (1) KR20160122127A (enExample)
CN (1) CN106459981A (enExample)
AU (1) AU2014373593B2 (enExample)
BR (1) BR112016014913A8 (enExample)
CA (1) CA2934818C (enExample)
IL (1) IL246371A0 (enExample)
MX (1) MX2016008355A (enExample)
RU (1) RU2016129724A (enExample)
SG (1) SG11201605093VA (enExample)
WO (1) WO2015095972A1 (enExample)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2015164723A1 (en) 2014-04-25 2015-10-29 The Trustees Of The University Of Pennsylvania Methods and compositions for treating metastatic breast cancer and other cancers in the brain
CN110214152B (zh) * 2016-10-14 2025-06-13 丹娜法伯癌症研究所公司 模块化四聚体双特异性抗体平台
DK3579848T3 (da) 2017-02-08 2025-01-20 Dragonfly Therapeutics Inc Multispecifikke bindende proteiner til aktivering af naturlige dræberceller og terapeutiske anvendelser heraf til behandling af kræft
KR20240060739A (ko) 2017-02-20 2024-05-08 드래곤플라이 쎄라퓨틱스, 인크. Her2, nkg2d 및 cd16에 결합하는 단백질
CN111093710A (zh) * 2017-07-13 2020-05-01 希望之城 硫代磷酸酯缀合的肽及其使用方法
WO2019014650A1 (en) * 2017-07-13 2019-01-17 City Of Hope ANTICANCER CONJUGATES OF PEPTIDE COUPLED WITH PHOSPHOROTHIOATE AND METHODS OF USE THEREOF
EP3925976A1 (en) * 2017-09-07 2021-12-22 Dragonfly Therapeutics, Inc. Proteins binding nkg2d, cd16 and a tumor-associated antigen
SG11202007482WA (en) 2018-02-08 2020-09-29 Dragonfly Therapeutics Inc Antibody variable domains targeting the nkg2d receptor
SG11202007579TA (en) 2018-02-08 2020-09-29 Dragonfly Therapeutics Inc Combination therapy of cancer involving multi-specific binding proteins that activate natural killer cells
JP7353576B2 (ja) 2018-02-20 2023-10-02 ドラゴンフライ セラピューティクス, インコーポレイテッド Cd33、nkg2d、及びcd16に結合する多重特異性結合タンパク質、ならびにその使用方法
KR20210005172A (ko) * 2018-05-01 2021-01-13 암브룩스, 인코포레이티드 항체 발현을 최적화하는 방법
EP3833385A4 (en) 2018-08-08 2021-12-22 Dragonfly Therapeutics, Inc. PROTEINS THAT BINDING NKG2D, CD16 AND A TUMOR-ASSOCIATED ANTIGEN
EP3833392A4 (en) 2018-08-08 2022-05-18 Dragonfly Therapeutics, Inc. MULTISPECIFIC BINDING PROTEINS FOR BINDING CD33, NKG2D AND CD16 AND METHODS OF USE
EA202091888A1 (ru) 2018-08-08 2020-10-23 Драгонфлай Терапьютикс, Инк. Вариабельные домены антител, нацеленные на рецептор nkg2d
KR102861586B1 (ko) 2018-11-30 2025-09-17 브리스톨-마이어스 스큅 컴퍼니 글루타민-함유 경쇄 c-말단 연장부를 포함하는 항체, 그의 접합체, 및 방법 및 용도
CN115836088A (zh) 2020-05-06 2023-03-21 蜻蜓疗法股份有限公司 结合nkg2d、cd16和clec12a的蛋白质
WO2022187539A1 (en) 2021-03-03 2022-09-09 Dragonfly Therapeutics, Inc. Methods of treating cancer using multi-specific binding proteins that bind nkg2d, cd16 and a tumor-associated antigen
CN115947830B (zh) * 2022-12-27 2023-09-12 优洛生物(上海)有限公司 一种经改造的抗体、其制备方法及其用途
EP4548936A1 (en) * 2023-10-30 2025-05-07 BioNTech SE Antibody-drug conjugates having a tailor-made drug-to-antibody ratio

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2170589C2 (ru) 1992-10-28 2001-07-20 Генентек Инк. Композиция для ингибирования ангиогенеза, моноклональное антитело, полипептид, способ ингибирования роста опухоли (варианты)
EP0676965B1 (en) * 1992-11-16 2007-07-25 Centocor Inc. Method of reducing immunogenicity of variable region of antibodies
US6165476A (en) 1997-07-10 2000-12-26 Beth Israel Deaconess Medical Center Fusion proteins with an immunoglobulin hinge region linker
US20050159343A1 (en) 1999-03-26 2005-07-21 Board Of Regents, University Of Texas System Inhibitors of glycosaminoglycans
US20030161809A1 (en) 2000-10-02 2003-08-28 Houston L. L. Compositions and methods for the transport of biologically active agents across cellular barriers
WO2005000902A1 (en) * 2003-06-30 2005-01-06 Mu-Hyeon Choe The dimer of chimeric recombinant binding domain-functional group fusion formed via disulfide-bond-bridge and the processes for producing the same
WO2007103288A2 (en) * 2006-03-02 2007-09-13 Seattle Genetics, Inc. Engineered antibody drug conjugates
CN105837690A (zh) * 2006-06-12 2016-08-10 新兴产品开发西雅图有限公司 具有效应功能的单链多价结合蛋白
ES2528922T3 (es) * 2007-07-16 2015-02-13 Genentech, Inc. Anticuerpos anti-CD79b humanizados e inmunoconjugados y métodos de uso
US20090155275A1 (en) 2007-07-31 2009-06-18 Medimmune, Llc Multispecific epitope binding proteins and uses thereof
EP2185188B1 (en) * 2007-08-22 2014-08-06 Medarex, L.L.C. Site-specific attachment of drugs or other agents to engineered antibodies with c-terminal extensions
EP2222709B1 (en) * 2007-11-30 2016-11-23 Glaxo Group Limited Antigen-binding constructs
US8454960B2 (en) * 2008-01-03 2013-06-04 The Scripps Research Institute Multispecific antibody targeting and multivalency through modular recognition domains
KR101658247B1 (ko) 2008-01-03 2016-09-22 더 스크립스 리서치 인스티튜트 모듈 인식 도메인을 통한 항체 표적화
WO2010042904A2 (en) * 2008-10-10 2010-04-15 Trubion Pharmaceuticals, Inc. Tcr complex immunotherapeutics
EP3385279B1 (en) * 2009-03-20 2020-02-26 Amgen Inc. Carrier immunoglobulins and uses thereof
CA2930801C (en) * 2010-11-05 2019-05-28 Rinat Neuroscience Corporation Engineered polypeptide conjugates and methods for making thereof using transglutaminase
US20120308584A1 (en) * 2011-05-08 2012-12-06 Legochem Biosciences, Inc. Protein-active agent conjugates and method for preparing the same
EP2714738B1 (en) 2011-05-24 2018-10-10 Zyngenia, Inc. Multivalent and monovalent multispecific complexes and their uses
PE20141212A1 (es) * 2011-06-22 2014-09-19 Hoffmann La Roche Eliminacion de celulas diana por parte de celulas t citotoxicas especificas de virus utilizando complejos que comprenden mhc de clase 1
ES2749349T3 (es) * 2011-11-07 2020-03-19 Medimmune Llc Proteínas de unión multiespecíficas y multivalentes y usos de las mismas
WO2013096829A2 (en) 2011-12-22 2013-06-27 Arizona Biomedical Research Commission Activation of cellular assault processes in the treatment of glioblastoma multiforme
MX2014010495A (es) * 2012-03-02 2014-11-14 Ablynx Nv Polipeptidos que enlazan a pcrv.
CA2891686A1 (en) 2012-12-18 2014-06-26 Novartis Ag Compositions and methods that utilize a peptide tag that binds to hyaluronan

Similar Documents

Publication Publication Date Title
JP2019520797A5 (enExample)
JP2019521643A5 (enExample)
RU2016129724A (ru) Антитела, содержащие с-концевые удлинения полипептида легкой цепи, их конъюгаты и способы применения
JP2019514361A5 (enExample)
JP2014528695A5 (enExample)
MX2022011411A (es) Proteinas de union a antigeno que se unen especificamente a mage-a.
WO2018057735A8 (en) Antibodies for siglec-15 and methods of use thereof
WO2020076977A3 (en) Dll3 single domain antibodies and therapeutic compositions thereof
JP2017529067A5 (enExample)
JP2019504617A5 (enExample)
JOP20190248A1 (ar) بروتينات ربط مولد ضد trem2 واستخداماته
JP2020063262A5 (enExample)
JP2012523848A5 (enExample)
JP2020506898A5 (enExample)
JP2017504578A5 (enExample)
MX2009012319A (es) Polipeptidos que se unen a receptores fc con funciones efectoras modificadas.
JP2015519055A5 (enExample)
NZ750366A (en) Chimeric antigen receptors targeting bcma and methods of use thereof
PE20221909A1 (es) Moleculas de union a antigeno que comprenden un trimero de ligando de la familia de tnf
JP2018526970A5 (enExample)
JP2012507994A5 (enExample)
RU2016106577A (ru) САЙТЫ АНТИТЕЛ, СПЕЦИФИЧНО СВЯЗЫВАЮЩИЕ EGFRvIII
JP2010533498A5 (enExample)
JP2012501669A5 (enExample)
JP2016536322A5 (enExample)